Literature DB >> 1680897

Immunohistochemical analysis of p53 and HER-2/neu proteins in human tumors.

K Chang1, I Ding, F G Kern, M C Willingham.   

Abstract

We examined samples of tumors of human breast, ovary, and colon of various degrees of malignancy for the expression of p53 protein, using a panel of anti-p53 antibodies and peroxidase immunohistochemistry. Of 66 tumor cases (24 cases of ovarian carcinoma, 23 cases of colon adenocarcinoma, and 19 cases of breast carcinoma), 36 (53%) showed high levels of expression of p53 using a human-specific antibody, and 16 (24%) showed high expression of a mutant form of p53. In the mutant p53-positive breast tumor samples, six (86%) were positive for HER-2/neu reactivity, compared with colon (0/4) and ovarian tumors (1/5). The pattern of p53 intracellular localization and tissue distribution, and the relationship between the expression of mutant p53 and cell differentiation, were also examined; poorly differentiated cells showed either overexpression of p53 or higher levels of mutant p53 in comparison with more normal cells.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1680897     DOI: 10.1177/39.9.1680897

Source DB:  PubMed          Journal:  J Histochem Cytochem        ISSN: 0022-1554            Impact factor:   2.479


  7 in total

1.  Molecular biomarkers for breast cancer prognosis: coexpression of c-erbB-2 and p53.

Authors:  S W Beenken; W E Grizzle; D R Crowe; M G Conner; H L Weiss; M T Sellers; H Krontiras; M M Urist; K I Bland
Journal:  Ann Surg       Date:  2001-05       Impact factor: 12.969

2.  Expression of cell cycle regulatory proteins (p53, pRb) in the human female genital tract.

Authors:  A Bukovsky; M R Caudle; J A Keenan; J Wimalasena; J S Foster; N B Upadhyaya; S E van Meter
Journal:  J Assist Reprod Genet       Date:  1995-02       Impact factor: 3.412

3.  Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer.

Authors:  H J Huang; P Neven; M Drijkoningen; R Paridaens; H Wildiers; E Van Limbergen; P Berteloot; F Amant; I Vergote; M R Christiaens
Journal:  J Clin Pathol       Date:  2005-06       Impact factor: 3.411

4.  Nuclear p53 protein accumulates preferentially in medullary and high-grade ductal but rarely in lobular breast carcinomas.

Authors:  W Domagala; B Harezga; A Szadowska; M Markiewski; K Weber; M Osborn
Journal:  Am J Pathol       Date:  1993-03       Impact factor: 4.307

5.  Coexpression of HER-2/neu and p53 is associated with a shorter disease-free survival in node-positive breast cancer patients.

Authors:  C Wiltschke; I Kindas-Muegge; A Steininger; A Reiner; G Reiner; P N Preis
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

6.  Abnormal p53 immunoreactivity and prognosis in node-negative breast carcinomas with long-term follow-up.

Authors:  S Bosari; A K Lee; G Viale; G J Heatley; G Coggi
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1992

7.  Exposure to depleted uranium does not alter the co-expression of HER-2/neu and p53 in breast cancer patients.

Authors:  Mais M Al-Mumen; Asad A Al-Janabi; Alaa S Jumaa; Kaswer M Al-Toriahi; Akeel A Yasseen
Journal:  BMC Res Notes       Date:  2011-03-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.